Browsing Tag
orforglipron
12 posts
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Can Novo Nordisk catch up—or will Lilly run away with the metabolic crown?
Explore how Eli Lilly and Company and Novo Nordisk are battling for dominance in the metabolic health market, and what could decide the next phase of the obesity drug race.
What’s next after Zepbound? Inside Eli Lilly and Company’s pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.
Eli Lilly (NYSE: LLY) to build $3bn Netherlands plant to power global obesity drug supply
Find out how Eli Lilly’s $3 billion Netherlands plant will reshape obesity drug manufacturing and strengthen Europe’s pharma supply chain resilience.
Lilly’s orforglipron proves oral GLP-1 power with impressive Phase 3 diabetes data
Find out how Eli Lilly’s oral GLP-1 drug orforglipron excelled in Phase 3 trials and could become a foundational therapy for type 2 diabetes.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.
Can oral GLP-1 pills match injected options in efficacy and patient adherence? What’s next for Wegovy and Rybelsus
Can oral GLP-1 drugs like Wegovy and orforglipron match injectables in weight loss and adherence? Discover what’s next in chronic obesity treatment.
How oral obesity drugs are changing treatment access: A look at semaglutide, amycretin, and orforglipron
Oral GLP-1 drugs like semaglutide, amycretin, and orforglipron are redefining obesity care. Explore trial data, payer impact, and what’s ahead for access and scale.
Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables.